GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

GSK plc GSK on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1 ...

Those are just a few of the classic storylines Lifetime movie fans expect to see when they switch on the TV, and, this summer, GSK is adding another real-life danger to Lifetime's lineup ...

GSK GSK1.80%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

While physician enthusiasm for depemokimab is more tempered compared to other pipeline agents, the therapy may still be well-positioned to meet critical needs in severe asthma management.

GSK plc GSK announced that it has signed an ... on the remaining three — Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...